In modern medicine, nanotechnology has a good present and better future. Industry is developing nanodrugs mainly in cancer but also in other pathologies. It is betting by multicomponent biocompatible drug delivery platforms. This evolution will allow us realize new Clinical Trials and obtain personalized therapies with an optimal profile of efficacy. However, previosly it must be solved some technical problems with respect to safety and toxicity of nanomaterials used and its handling. Thus, regulatory agencies should establish laws and rules about use of these nanomaterials, as well as specific guidelines on all products currently used in nanomedicine.